Request for Covid-19 Impact Assessment of this Report

Pharmaceuticals

United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Research Report Forecast 2017-2021

  • SPI2255289
  • 105 Pages
  • November 2017
  • Pharmaceuticals
Download Sample    Get Discount   
 
The United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Research Report Forecast 2017-2021 is a valuable source of insightful data for business strategists. It provides the Non-alcoholic Fatty Liver Disease (NAFLD) Drug industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Non-alcoholic Fatty Liver Disease (NAFLD) Drug market study provides comprehensive data which enhances the understanding, scope and application of this report.

This report provides comprehensive analysis of

Key market segments and sub-segments

Evolving market trends and dynamics

Changing supply and demand scenarios

Quantifying market opportunities through market sizing and market forecasting

Tracking current trends/opportunities/challenges

Competitive insights

Opportunity mapping in terms of technological breakthroughs

The Major players reported in the market include:

Conatus Pharmaceuticals

Daewoong Pharmaceutical

Galmed International

Kyorin Pharmaceutical

Metabolic Solutions Development

Novartis AG

Phenex Pharmaceuticals

Raptor Pharmaceuticals

TCM Biotech International

...

United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market: Product Segment Analysis

Type 1

Type 2

Type 3

United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market: Application Segment Analysis

Application 1

Application 2

Application 3

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments


Table Of Contents
United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Research Report Forecast 2017-2021

Chapter 1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Overview

1.1 Product Overview and Scope of Non-alcoholic Fatty Liver Disease (NAFLD) Drug

1.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Segmentation by Type

1.2.1 United States Production Market Share of Non-alcoholic Fatty Liver Disease (NAFLD) Drug by Type in 2015

1.2.1 Type 1

1.2.2 Type 2

1.2.3 Type 3

1.3 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Segmentation by Application

1.3.1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Market Share by Application in 2015

1.3.2 Application 1

1.3.3 Application 2

1.3.4 Application 3

1.4 United States Market Size Sales (Value) and Revenue (Volume) of Non-alcoholic Fatty Liver Disease (NAFLD) Drug (2011-2021)

Chapter 2 United States Economic Impact on Non-alcoholic Fatty Liver Disease (NAFLD) Drug Industry

2.1 United States Macroeconomic Analysis

2.2 United States Macroeconomic Environment Development Trend

Chapter 3 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Competition by Manufacturers

3.1 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production and Share by Manufacturers (2015 and 2016)

3.2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Share by Manufacturers (2015 and 2016)

3.3 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Average Price by Manufacturers (2015 and 2016)

3.4 Manufacturers Non-alcoholic Fatty Liver Disease (NAFLD) Drug Manufacturing Base Distribution, Production Area and Product Type

3.5 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Competitive Situation and Trends

3.5.1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Concentration Rate

3.5.2 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share of Top 3 and Top 5 Manufacturers

3.5.3 Mergers & Acquisitions, Expansion

Chapter 4 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue (Value), Price Trend by Type

4.1 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production and Market Share by Type (2012-2017)

4.2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Market Share by Type (2012-2017)

4.3 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Price by Type (2012-2017)

4.4 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production Growth by Type (2012-2017)

Chapter 5 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Analysis by Application

5.1 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption and Market Share by Application (2012-2017)

5.2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Growth Rate by Application (2012-2017)

5.3 Market Drivers and Opportunities

5.3.1 Potential Applications

5.3.2 Emerging Markets/Countries

Chapter 6 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Manufacturers Analysis

6.1 Conatus Pharmaceuticals

6.1.1 Company Basic Information, Manufacturing Base and Competitors

6.1.2 Product Type, Application and Specification

6.1.3 Production, Revenue, Price and Gross Margin (2012-2017)

6.1.4 Business Overview

6.2 Daewoong Pharmaceutical

6.2.1 Company Basic Information, Manufacturing Base and Competitors

6.2.2 Product Type, Application and Specification

6.2.3 Production, Revenue, Price and Gross Margin (2012-2017)

6.2.4 Business Overview

6.3 Galmed International

6.3.1 Company Basic Information, Manufacturing Base and Competitors

6.3.2 Product Type, Application and Specification

6.3.3 Production, Revenue, Price and Gross Margin (2012-2017)

6.3.4 Business Overview

6.4 Kyorin Pharmaceutical

6.4.1 Company Basic Information, Manufacturing Base and Competitors

6.4.2 Product Type, Application and Specification

6.4.3 Production, Revenue, Price and Gross Margin (2012-2017)

6.4.4 Business Overview

6.5 Metabolic Solutions Development

6.5.1 Company Basic Information, Manufacturing Base and Competitors

6.5.2 Product Type, Application and Specification

6.5.3 Production, Revenue, Price and Gross Margin (2012-2017)

6.5.4 Business Overview

6.6 Novartis AG

6.6.1 Company Basic Information, Manufacturing Base and Competitors

6.6.2 Product Type, Application and Specification

6.6.3 Production, Revenue, Price and Gross Margin (2012-2017)

6.6.4 Business Overview

6.7 Phenex Pharmaceuticals

6.7.1 Company Basic Information, Manufacturing Base and Competitors

6.7.2 Product Type, Application and Specification

6.7.3 Production, Revenue, Price and Gross Margin (2012-2017)

6.7.4 Business Overview

6.8 Raptor Pharmaceuticals

6.6.1 Company Basic Information, Manufacturing Base and Competitors

6.6.2 Product Type, Application and Specification

6.6.3 Production, Revenue, Price and Gross Margin (2012-2017)

6.6.4 Business Overview

6.9 TCM Biotech International

6.9.1 Company Basic Information, Manufacturing Base and Competitors

6.9.2 Product Type, Application and Specification

6.9.3 Production, Revenue, Price and Gross Margin (2012-2017)

6.9.4 Business Overview

Chapter 7 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Manufacturing Cost Analysis

7.1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Price Trend of Key Raw Materials

7.1.3 Key Suppliers of Raw Materials

7.1.4 Market Concentration Rate of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.2.1 Raw Materials

7.2.2 Labor Cost

7.2.3 Manufacturing Expenses

7.3 Manufacturing Process Analysis of Non-alcoholic Fatty Liver Disease (NAFLD) Drug

Chapter 8 Industrial Chain, Sourcing Strategy and Downstream Buyers

8.1 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Industrial Chain Analysis

8.2 Upstream Raw Materials Sourcing

8.3 Raw Materials Sources of Non-alcoholic Fatty Liver Disease (NAFLD) Drug Major Manufacturers in 2015

8.4 Downstream Buyers

Chapter 9 Marketing Strategy Analysis, Distributors/Traders

9.1 Marketing Channel

9.1.1 Direct Marketing

9.1.2 Indirect Marketing

9.1.3 Marketing Channel Development Trend

9.2 Market Positioning

9.2.1 Pricing Strategy

9.2.2 Brand Strategy

9.2.3 Target Client

9.3 Distributors/Traders List

Chapter 10 Market Effect Factors Analysis

10.1 Technology Progress/Risk

10.1.1 Substitutes Threat

10.1.2 Technology Progress in Related Industry

10.2 Consumer Needs/Customer Preference Change

10.3 Economic/Political Environmental Change

Chapter 11 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Forecast (2017-2021)

11.1 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue Forecast (2017-2021)

11.2 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Consumption Forecast by Regions (2017-2021)

11.3 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production Forecast by Type (2017-2021)

11.4 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Forecast by Application (2017-2021)

11.5 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Price Forecast (2017-2021)

Chapter 12 Appendix

Figure Picture of Non-alcoholic Fatty Liver Disease (NAFLD) Drug

Table Classification of Non-alcoholic Fatty Liver Disease (NAFLD) Drug

Figure United States Sales Market Share of Non-alcoholic Fatty Liver Disease (NAFLD) Drug by Type in 2015

Table Application of Non-alcoholic Fatty Liver Disease (NAFLD) Drug

Figure United States Sales Market Share of Non-alcoholic Fatty Liver Disease (NAFLD) Drug by Application in 2015

Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales and Growth Rate (2011-2021)

Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate (2011-2021)

Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales of Key Manufacturers (2015 and 2016)

Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Share by Manufacturers (2015 and 2016)

Figure 2015 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Share by Manufacturers

Figure 2016 Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Share by Manufacturers

Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue by Manufacturers (2015 and 2016)

Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue Share by Manufacturers (2015 and 2016)

Table 2015 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue Share by Manufacturers

Table 2016 United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue Share by Manufacturers

Table United States Market Non-alcoholic Fatty Liver Disease (NAFLD) Drug Average Price of Key Manufacturers (2015 and 2016)

Figure United States Market Non-alcoholic Fatty Liver Disease (NAFLD) Drug Average Price of Key Manufacturers in 2015

Figure Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share of Top 3 Manufacturers

Figure Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share of Top 5 Manufacturers

Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Type (2012-2017)

Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Share by Type (2012-2017)

Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share by Type in 2015

Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Market Share by Type (2012-2017)

Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue Share by Type (2012-2017)

Figure Revenue Market Share of Non-alcoholic Fatty Liver Disease (NAFLD) Drug by Type (2012-2017)

Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Price by Type (2012-2017)

Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Growth Rate by Type (2012-2017)

Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales by Application (2012-2017)

Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share by Application (2012-2017)

Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Market Share by Application in 2015

Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Growth Rate by Application (2012-2017)

Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Sales Growth Rate by Application (2012-2017)

Table Conatus Pharmaceuticals Basic Information, Manufacturing Base, Production Area and Its Competitors

Table Conatus Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue, Price and Gross Margin (2012-2017)

Table Conatus Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share (2012-2017)

Table Daewoong Pharmaceutical Basic Information, Manufacturing Base, Production Area and Its Competitors

Table Daewoong Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue, Price and Gross Margin (2012-2017)

Table Daewoong Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share (2012-2017)

Table Galmed International Basic Information, Manufacturing Base, Production Area and Its Competitors

Table Galmed International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue, Price and Gross Margin (2012-2017)

Table Galmed International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share (2012-2017)

Table Kyorin Pharmaceutical Basic Information, Manufacturing Base, Production Area and Its Competitors

Table Kyorin Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue, Price and Gross Margin (2012-2017)

Table Kyorin Pharmaceutical Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share (2012-2017)

Table Metabolic Solutions Development Basic Information, Manufacturing Base, Production Area and Its Competitors

Table Metabolic Solutions Development Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue, Price and Gross Margin (2012-2017)

Table Metabolic Solutions Development Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share (2012-2017)

Table Novartis AG Basic Information, Manufacturing Base, Production Area and Its Competitors

Table Novartis AG Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue, Price and Gross Margin (2012-2017)

Table Novartis AG Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share (2012-2017)

Table Phenex Pharmaceuticals Basic Information, Manufacturing Base, Production Area and Its Competitors

Table Phenex Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue, Price and Gross Margin (2012-2017)

Table Phenex Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share (2012-2017)

Table Raptor Pharmaceuticals Basic Information, Manufacturing Base, Production Area and Its Competitors

Table Raptor Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue, Price and Gross Margin (2012-2017)

Table Raptor Pharmaceuticals Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share (2012-2017)

Table TCM Biotech International Basic Information, Manufacturing Base, Production Area and Its Competitors

Table TCM Biotech International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production, Revenue, Price and Gross Margin (2012-2017)

Table TCM Biotech International Non-alcoholic Fatty Liver Disease (NAFLD) Drug Market Share (2012-2017)

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Non-alcoholic Fatty Liver Disease (NAFLD) Drug

Figure Manufacturing Process Analysis of Non-alcoholic Fatty Liver Disease (NAFLD) Drug

Figure Non-alcoholic Fatty Liver Disease (NAFLD) Drug Industrial Chain Analysis

Table Raw Materials Sources of Non-alcoholic Fatty Liver Disease (NAFLD) Drug Major Manufacturers in 2015

Table Major Buyers of Non-alcoholic Fatty Liver Disease (NAFLD) Drug

Table Distributors/Traders List

Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production and Growth Rate Forecast (2017-2021)

Figure United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Revenue and Growth Rate Forecast (2017-2021)

Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Production Forecast by Type (2017-2021)

Table United States Non-alcoholic Fatty Liver Disease (NAFLD) Drug Consumption Forecast by Application (2017-2021)

 
Purchase Options

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Contact Us

+ 1-888-961-4454

Drop Us an email at

help@bigmarketresearch.com

Similar Reports

Protein Therapeutics Market by Product (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, and Follicle Stimulating Hormone) and Application (Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to rea...

  • Publish Date: November 14, 2017
  • $5370
Global Cord Blood Banking Services (Stem Cell) Market, Size, Share, Trends, Forecast, Global Analysis, Research, Report, Segmentation, and Future Demand, 2012 - 2020

Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in th...

  • Publish Date: July 20, 2017
  • $5370